Showing 8381-8390 of 9758 results for "".
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/novan-phase-2b-data-for-sb204-gel-to-be-presented-at-fall-clinical-dermatology-conference/2458396/Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. The presentation wil
- Dr. Ken Washenik Named New President of International Society of Hair Restoration Surgeryhttps://practicaldermatology.com/news/dr-ken-washenik-named-new-president-of-international-society-of-hair-restoration-surgery/2458394/The International Society of Hair Restoration Surgery (ISHRS), a global non-profit medical association and a leading authority on hair loss treatment and restoration, elected Ken Washenik, MD, PhD, FISHRS, as President. The announcement took place at the ISHRS 24th</
- New from NeoStrata: Introducing the ProSystem Retinol Peelhttps://practicaldermatology.com/news/new-from-neostrata-the-prosystem-retinol-peel/2458398/NeoStrata is rolling out the NeoStrata ProSystem Retinol Peel, the first retinol peel for the brand. The peel contains 3% Retinol plus Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and wrinkles, help reduce acne,
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- Research Elucidates Skin Phenotype of Pediatric Eczemahttps://practicaldermatology.com/news/research-elucidates-skin-phenotype-of-pediatric-eczema/2458426/Pediatric atopic dermatitis (AD) in infants looks a lot different than adult AD, suggesting the need for alternative, and possibly more aggressive, treatment strategies in children. The study, led by researchers at the Icahn School of Medicine at Mount Sina
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- Skin Cancer Prevention Barriers Cited in Uninsured, Minority, Immigrant Populationshttps://practicaldermatology.com/news/skin-cancer-prevention-barriers-cited-in-uninsured-minority-immigrant-populations/2458434/Lack of knowledge, the belief that dark skin is protective, and the dislike of sun protection are barriers to skin cancer prevention in minority and immigrant populations, according to a new study in JAMA Dermatology.
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).